Composition
1 sachet contains: active ingredients: probiotic Streptococcus salivarius K12 (not less than 1x109 CFU (not less than one billion viable colony-forming units in 1 sachet) – 50 mg (mg), vitamin D3 (cholecalciferol) – 5 mcg (mcg).
Excipients: bulking agent maltodextrin, dietary fiber fructooligosaccharides, strawberry flavoring. GMO-free. The product contains traces of milk and dairy products (including lactose). Gluten-free. With strawberry flavor.
Nutritional (nutritional) and energy value (calories) of the product per 1 sachet: energy value (calories) 20.54 kJ (kJ) / 4.92 kcal (kcal); fats 0.0003 g (g), of which saturated 0.00015 g (g); carbohydrates 1.01 g (g), of which sugars 0.0775 g (g); dietary fiber 0.4096 g (g); proteins 0.0072 g (g); salt 0 g (g).
Properties
Scientific confirmation of the action of Bactoblis components: Streptococcus salivarius K12 (BLIS K12) is a strain of beneficial bacteria that is normally present and makes up to 40% of the total population of bacteria in a healthy oral cavity. The action of Streptococcus salivarius K12 (Bactoblis) is carried out by colonizing the oral cavity and nasopharynx, i.e. it is a respiratory probiotic.
Streptococcus salivarius K12 actively inhibits the growth of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, Staphylococcus aureus, Proteus vulgaris, Proteus spp., Candida albicans, Klebsiella pneumoniae, Streptococcus mutans, Staphylococcus epidermidis, which are among the main etiological factors of bacterial infections of the respiratory tract in children.
The probiotic Streptococcus salivarius K12 produces two antibacterial bacteriocins (salivaricin A2, salivaricin B), which inhibit the growth of pathogens in the oropharynx. Streptococcus salivarius K12 in Bactoblis has a GRAS status according to the letter of the US Food and Drug Administration (USFDA) in response to GRAS Notice No. GRN 000591 (2015). History of the creation of Streptococcus salivarius K12 (BLIS K12) BLIS K12 was created by Professor of Microbiology, Dr. John Tagg from the University of Otago in New Zealand. In one of his first studies, after a long observation of school-age children in Dunedin, New Zealand, Professor Tagg noticed an interesting detail: some children did not develop throat diseases as often as others. In a microbiological study of salivary smears, Professor Tagg discovered that in the saliva of children who had less frequent throat infections, there were certain types of beneficial bacteria that were not present in other children. These bacteria produce natural antimicrobial substances, which Professor Tagg called BLIS - bacteriocin-like inhibitory substances. The professor isolated the main strain of the genus Streptococcus salivarius - beneficial bacteria that are normally present and make up up to 40% of the total population of bacteria in a healthy oral cavity. After many years of work to improve the probiotic qualities of this strain, the patented probiotic BLIS K12 was obtained - the world's first probiotic for normalizing the microflora of the upper respiratory tract, in particular the oral cavity.
Bactoblis® (orodispersible sachets) is a respiratory orodispersible probiotic containing the world’s first probiotic strain of Streptococcus salivarius K12 for oral administration, which is patented to help support the body’s defenses against infectious diseases of the upper respiratory tract and reduce the number of cases of complications from possible infections. Vitamin D3 (cholecalciferol), which is part of the dietary supplement Bactoblis®, has been used in medical practice for decades due to its ability to influence a number of metabolic processes and change the functional state of various organs and systems.
Vitamin D receptors have been identified in cells of the skin, heart, lungs, brain, skeletal muscles, endocrine glands, and bone tissue. They are widely represented on cells of the immune system, in particular on activated CD4+ and CD8+ lymphocytes, T-lymphocytes, B-lymphocytes, neutrophils, and macrophages. For a long time, vitamin D has been used in pediatric practice for the prevention and treatment of rickets, a disease that develops when there is insufficient intake of vitamin D into the body. In recent years, an important role of this vitamin in the functioning of the immune system has been established. It has been proven that it stimulates innate immunity, promotes the differentiation of monocytes into macrophages, suppresses antigen-presenting function, increases the expression of anti-inflammatory cytokines, and reduces the formation of pro-inflammatory cytokines such as TNF, IL6, IL8, and IL12, thereby reducing the manifestations of inflammation in the area of the pathological process. The body's innate immune responses against upper respiratory tract infections are closely linked to the production of antibacterial peptides - molecules with bactericidal activity.
Under the influence of vitamin D, transcription of such peptides is activated, which have a wide spectrum of action against many types of bacteria, viruses and fungi. The preventive amount of vitamin D3 for young children is 400 IU (10 mcg)/day, i.e. its amount in the dietary supplement Bactoblis® is about 50% of the recommended daily amount for patients of the corresponding age.
Recommendations for use
Use for adults and children aged 6 months and over as an additional source of probiotic Streptococcus Salivarius K12 and vitamin D3 to create optimal conditions for:
- effective colonization of the oral cavity, oropharynx and nasopharynx with beneficial bacteria, protection of the mucosa from infection by pathogens that cause upper respiratory tract infections;
- increasing the body's resistance to infections, particularly during seasonal illnesses and with frequently recurring infections of the ears, throat, and nose;
- reducing the incidence of common viral infections of the upper respiratory tract;
- colonization with beneficial bacteria of the middle ear as an adjunct in the complex therapy of secretory otitis media;
- reducing the number of cases of use of antibiotics and antipyretic drugs used to combat upper respiratory tract infections;
- maintaining normal microbiocenosis of the upper respiratory tract, including the oral cavity, particularly in children adapting to children's groups;
- prevention of bacterial complications of acute respiratory viral infections caused by bacteria whose growth is inhibited by Streptococcus Salivarius K12;
- restoration of the microflora of the upper respiratory tract, including the oropharynx, after a course of antibiotics;
- prevention of relapses and re-infection with SARS.
Dietary supplement Bactoblis / Bactoblis® (orodispersible sachets). Not a medicinal product. Dietary supplement cannot be a substitute for a complete and balanced diet and a healthy lifestyle. It is recommended to consult a doctor before consumption.
Method of administration and doses
Children from 6 months and adults: 1 sachet per day in the evening before bedtime, after brushing teeth. The contents of the sachet should be poured directly into the mouth and sucked until completely dissolved.
For babies from 6 months who cannot suck, empty the contents of the sachet into a clean dish. Dip a wet pacifier into the powder. Then place the pacifier with the powder in the baby's mouth and wait about 30 seconds for the powder to dissolve. Repeat until the powder is used up.
If the child does not use a pacifier, the contents of the sachet can be dissolved in a small amount of water (approximately 2.5 ml (ml)) and given to the child in small portions from a spoon over approximately 5 min (minutes). After taking the dietary supplement, it is recommended not to consume food or water for at least 30 min (minutes).
Recommended method of application:
- at the first signs of respiratory diseases – 10 days, unless otherwise prescribed by a doctor;
- after taking antibiotics – 30 days, unless the doctor prescribes otherwise;
- to prevent the incidence of SARS in the cold season (autumn-spring) and with frequently recurring (recurrent) infections of the ear, throat or nose - 2 courses of 30 days with an interval of 90 days or one course of 90 days, unless otherwise prescribed by a doctor;
- to eliminate bad breath – 10-15 days.
A course of use exceeding 90 days must be agreed with a doctor. Do not exceed the recommended amount for daily consumption. Do not consume simultaneously with antibiotics. You can start consuming Bactoblis the day after taking the last dose of antibiotics.
Use during pregnancy and lactation
It is recommended to consult a doctor prior to use.
Reservation
Hypersensitivity to individual components of the dietary supplement.
Release form
10 orodispersible sachets packed in a cardboard box.
Net weight of 1 sachet: 1500 mg (mg) ± 10.0%.
Net weight of sachet contents in the package: 10 pcs.: 15 g (g) ± 10.0%. The end date of the minimum shelf life "Best before (month/year)": indicated on the package.
Storage conditions
Store in the original packaging in a dry place at a temperature not exceeding 25 ° C. Keep out of the reach of children!
Producer
Bluestone Pharma, Rathausstrasse 14, CH – 6340 Baar, Switzerland.
Address of production facilities: Republic of Serbia, 18000 Niš, Svetog Cara Konstantina 82-86.
Importer and contact person in Ukraine: LLC "Zdravo", 04114, Kyiv, Avtozavodska St., 54/19, letter A.
